How'd you fix Pear Therapeutics's revenue issues in 2026?

Pear Therapeutics is not a 2026 revenue story—it's a post-bankruptcy IP acquisition play. Click Therapeutics (actual buyer) and a 2026 successor need to: (1) Pivot reSET, reSET-O, and Somryst from prescription-reimbursement (dead) to direct-pay + employer-benefits model (B2B2C), (2) Stack employer-coverage with EAP integration (Pavilion for sales playbooks, Akili Interactive's partnership model as reference), and (3) License the FDA-cleared digital-therapeutic assets to Hinge Health and Omada as white-label backend—flip from consumer subscription to B2B recurring revenue via health plans and pharma-backed employer coalitions.

What's Actually Broken

1. Payer-reimbursement collapse (2022-2023): FDA-cleared but zero coverage. Pear had reSET (opioid use disorder) and reSET-O (opioid use disorder in underserved areas) and Somryst (insomnia) FDA-cleared, but Medicare, commercial plans, and Medicaid refused to code them. Reimbursement pricing fell from $5,000-10,000/treatment to $0. Revenue model evaporated overnight.

1. Prescription-app friction kills consumer adoption. reSET required MD prescription + 8-week coaching protocol. Patient friction was brutal—most prescribed patients never downloaded. Pear's 2023 user base was ~150K cumulative (not active), vs. HelloFresh at 3M+ subscribers or Hinge Health at 5M+. Conversion was single-digit %.

1. Chapter 11 bankruptcy + brand toxicity (June 2023). Pear filed Ch11 after burning $300M+ in VC/debt. Assets split: Click Therapeutics bought reSET/reSET-O, Welkin Health bought SaMD ops platform. Post-bankruptcy brand = "failed startup," not "FDA-cleared therapeutic." Zero enterprise deals signed during Ch11 exclusivity.

1. Founder departure + governance breakdown. Corey McCann (founder/CEO) exited pre-bankruptcy. Board unable to pivot from venture-scale ($50M+ ARR fantasy) to "defensible $10-20M niche." No executive bandwidth for enterprise GTM until asset sale completed.

1. FDA clearance paradox: regulatory moat + reimbursement prison. FDA 510(k) clearance was supposed to be Pear's moat. Instead, it locked Pear into medical-device reimbursement rules (CPT codes, prior auth, payer negotiation). Competitors (Big Health, Omada, Hinge) side-stepped FDA entirely and captured employer/consumer market with unregulated apps + better UX.

2026 Fix Playbook

1. Acquirer relaunch: Direct-pay + employer-benefits bifurcation. Click Therapeutics (or Pear 2.0 under new ownership) splits: (A) B2C direct-pay tier ($30–50/mo for insomnia/substance-use support, no MD prescription) + (B) B2B2C employer-EAP integration ($5–8 PEPM). Kill the Medicare/Medicaid bet entirely.

1. Employer-coverage motion via Pavilion fractional VP Sales. Hire vertical sales leader to own $50k+ ACV contracts with Fortune 500 benefits teams. Use Pavilion sales playbooks ("digital-therapeutics for substance abuse" in benefits bundles). Target employers self-insuring above $500M payroll.

1. Akili Interactive partnership model as reference. Akili (ADHD digital app, FDA-cleared like Pear) pivoted to employer-backed SaMD partnerships. Pear should license reSET/Somryst IP to health plans and pharma-backed coalitions at $2–5 per member per month, not pursue direct-reimbursement.

1. Medicare D coding play: Substance-use screening as preventive service. Pear should layer reSET as a "preventive benefit" under Medicare Part D (not Part A/B reimbursement). Package as generic opioid-use screening + brief intervention + app access. Adds $20–40/member/year in plan revenue.

1. White-label licensing to Hinge Health and Omada. Pear's FDA-cleared SaMD engine (reSET behavior-change algorithms) has 10+ years of clinical validation. Hinge Health and Omada lack that. Pear licenses the backend to both, takes 15–25% of B2B revenue from their health-plan deals. Zero CAC, recurring, defensible.

1. Bridge Group for peer benchmarking in SaMD sales cycles. Bridge Group (RevOps benchmarking) should publish "Digital-Therapeutics Sales Benchmarks 2026" to standardize Pear's sales metrics vs. Incumbents (Omada ARR/logo-churn, Hinge Health CAC payback). Pear uses published data to accelerate enterprise sales closes.

1. Force Management for "Win/Loss Analysis on Pear vs. Omada/Hinge/Big Health." Post-deal interviews reveal why employers pick Hinge over reSET (brand strength, integrated care claim, outcomes reporting). Force Management helps Pear refine competitor-differentiation messaging + sales training.

Table

Mermaid

FAQ

Why did Pear Therapeutics' reimbursement model collapse? Pear had reSET, reSET-O, and Somryst FDA-cleared, but Medicare, commercial plans, and Medicaid refused to code them. Reimbursement pricing fell from $5,000–10,000 per treatment to $0, evaporating the revenue model overnight.

The 510(k) clearance that was meant to be a moat instead locked Pear into medical-device reimbursement rules while unregulated competitors captured the market.

What is the direct-pay and employer-benefits bifurcation the plan proposes? The acquirer relaunch splits into a B2C direct-pay tier at $30–50/mo for insomnia and substance-use support with no MD prescription, plus a B2B2C employer-EAP integration at $5–8 PEPM. It kills the Medicare and Medicaid bet entirely.

Pavilion's fractional VP Sales would own the $50k+ ACV employer contracts targeting employers self-insuring above $500M payroll.

How does the Akili Interactive model serve as a reference for Pear? Akili is an ADHD digital app that was FDA-cleared like Pear and pivoted to employer-backed SaMD partnerships. Following that model, Pear should license reSET and Somryst IP to health plans and pharma-backed coalitions at $2–5 per member per month.

That replaces the dead direct-reimbursement approach with recurring B2B revenue.

Why white-label Pear's engine to Hinge Health and Omada? Pear's FDA-cleared SaMD engine carries 10+ years of clinical validation that Hinge Health and Omada lack. Licensing the reSET behavior-change backend to both lets Pear take 15–25% of the B2B revenue from their health-plan deals.

It is described as zero-CAC, recurring, and defensible revenue.

What is the projected revenue and churn shift from this pivot? The table projects reimbursement moving from $0 to $15–25M ARR via employer PEPM and a Medicare D preventive play. Churn improves from 8–12% monthly DTC to 2–3% annual under B2B employer contracts with SLAs. The total addressable market expands from roughly $500M to $5B+ across employer and health-plan segments.

Bottom Line

Pear's 2026 play is not rescuing the company—it's monetizing the FDA-cleared digital-therapeutic IP by pivoting from broken payer-reimbursement to employer-benefits + white-label licensing to health plans, with a $25M+ ARR exit target by 2027.

TAGS

Pear-therapeutics, digital-therapeutics, post-bankruptcy, fda-cleared, drip-company-fix, click-therapeutics, employer-benefits, samu, substance-use-disorder, insomnia, akili-interactive, hinge-health, omada, pavilion-sales, bridge-group, force-management, medicare-d, white-label-licensing